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Abstract 
Cognitive behavioral therapy for psychosis (CBTp) involves helping patients to understand 
and reframe threatening appraisals of their psychotic experiences to reduce distress and 
increase functioning. Whilst CBTp is effective for many, it is not effective for all patients and 
the factors predicting a good outcome remain poorly understood. Machine learning is a 
powerful approach that allows new predictors to be identified in a data-driven way, which 
can inform understanding of the mechanisms underlying therapeutic interventions, and 
ultimately make predictions about symptom improvement at the individual patient level. 
Thirty-eight patients with a diagnosis of schizophrenia completed a social affect task during 
functional MRI. Multivariate pattern analysis assessed whether treatment response in those 
receiving CBTp (n=22) could be predicted by pre-therapy neural responses to facial affect 
that was either threat-related (ambiguous ‘neutral’ faces perceived as threatening in 
psychosis, in addition to angry and fearful faces) or prosocial (happy faces). The models 
predicted improvement in psychotic (r=0.63, p=0.003) and affective (r=0.31, p=0.05) 
symptoms following CBTp, but not in the treatment-as-usual group (n=16). Psychotic 
symptom improvement was predicted by neural responses to threat-related affect across 
sensorimotor and frontal-limbic regions, whereas affective symptom improvement was 
predicted by neural responses to fearful faces only as well as prosocial affect across 
sensorimotor and frontal regions. These findings suggest that CBTp most likely improves 
psychotic and affective symptoms in those endorsing more threatening appraisals and mood-
congruent processing biases, respectively, which are explored and reframed as part of the 
therapy.  This study improves our understanding of the neurobiology of treatment response 
and provides a foundation that will hopefully lead to greater precision and tailoring of the 
interventions offered to patients.  
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Introduction 
The functional neurobiological underpinning of positive psychotic and affective symptoms in 
schizophrenia has been extensively studied1–9 and there is considerable promise in using 
these neurobiological markers to improve the precision of interventions at the individual 
patient level10. To date, four studies have examined the neural predictors of cognitive 
behavioral therapy for psychosis (CBTp) treatment outcomes11–14, the primary psychological 
intervention for this patient group15. However, none of these studies used machine learning 
methods to investigate neural predictors at the individual patient level. Currently, only three 
studies have made successful predictions about individual CBT treatment outcomes using 
such analytical approaches, none of which was in schizophrenia patients16–18. However, 
individual predictions are an important step towards better tailoring of treatment by utilising 
patient-specific markers to provide an objective estimate of treatment outcomes. 
Incorporation of neural predictors into existing assessment procedures can inform clinical 
decision-making regarding the use of additional psychological therapies to improve treatment 
effectiveness19 and the resources that support CBTp. This is crucial considering that only 
approximately 50% of patients may experience clinically significant improvement following 
CBTp20 and limited clinical service resources mean that, even in the UK where it is a 
NICE21-recommended treatment, only approximately 10% of patients receive therapy in 
routine services22. 
 
Supervised machine learning methods, such as multivariate pattern analysis, are a powerful 
tool for identifying the neural predictors of treatment response since the analysis involves 
building an algorithm that can make predictions at the individual patient level23. This data-
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driven approach can detect subtle patterns of distributed activity predicting clinical 
outcomes23, such as treatment outcomes or disorder course. Brain responses to clinically 
relevant stimuli may be most likely to yield meaningful predictions about symptom 
improvement. A highly replicated finding in psychosis is a bias towards perceiving facial 
expressions as threatening, including evidence for the misattribution of threat to neutral facial 
expressions24,25, which has been put forward as one route to paranoia25–27. Neuroimaging 
markers for this bias include elevated responses in a number of regions involved in threat 
perception and emotion processing24,28,29. This network includes a number of limbic regions, 
including the amygdala, hippocampus and insula, as well as visual and motor areas28,30,31. 
The amygdala and insula are part of the ventral network which includes the anterior cingulate 
and the ventrolateral prefrontal cortex (PFC), whereas the hippocampus belongs to the dorsal 
system which includes the dorsolateral and dorsomedial PFC25. The latter is involved in the 
regulation of emotions whereas the former is important for threat appraisal25,32. Sensorimotor 
regions, together with frontal regions, are crucial for the development of behavioural 
responses in a context-dependent matter33. Neuroimaging studies on affective face processing 
have reported reduced activation in frontal areas, but increased activation in threat and 
sensorimotor regions in patients with psychosis in comparison to healthy controls28,29. In 
particular, the misattribution of threat to neutral stimuli has been associated with increased 
activation in the precentral and postcentral gyrus as well as the parietal lobule34. Elevated 
threat-related activity in response to neutral facial expressions suggests they are not neutral in 
psychosis, which seems consistent with the interpretation of a heightened tendency to 
perceive threat when facial expressions are ambiguous24,25,27. The evidence for increased 
activation for both ambiguous and threatening affect suggests the facial affect task is highly 
sensitive to aberrant threat and salience processing in psychosis. Additionally, evidence for 
reduced brain activation responses to happy facial expressions in major depression35,36 
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suggests the task is sensitive to altered processing of prosocial affect in those who experience 
depressive symptoms. Moreover, differences in task activation have been shown to relate to 
both the type and severity of symptoms37,38, making the facial affect task a potential assay for 
predicting post-therapy improvement in psychotic and affective symptoms.  
 
CBTp is an effective intervention for psychosis39 and is accompanied by improvements in 
social, occupational, and psychological functioning20,40. The primary aim of CBTp is helping 
patients to understand and reframe threatening appraisals of their psychotic experiences, 
become less distressed and live a personally meaningful life41,42. Affective symptoms are 
frequently reported in psychosis43 and are a common target of therapy by emphasising 
techniques that help patients recognise and change mood-congruent biases and unhelpful 
thinking styles41,44, with evidence of reduced depression following CBTp45,46. One neural 
mechanism proposed to underlie treatment effects in CBTp involves an increased recruitment 
of higher-order brain networks to regulate brain regions involved in threat and salience 
perception47. This has been probed experimentally using the facial affect processing task, 
which has shown that improvement in positive psychotic symptoms47,48 and depressive 
symptoms47 correlates with changes in functional neurobiology47–49. In particular, CBTp-led 
reductions in activation of the threat network in response to affective stimuli48 and 
concomitant increases in connectivity between the left amygdala and inferior parietal lobule 
correlated with improvement in positive symptoms of psychosis47. These post-CBTp 
connectivity changes between the amygdala and the inferior parietal lobule as well as the 
dorsolateral PFC have also been found to be predictive of long-term affective and psychotic 
symptoms across several years49. Whilst these studies have provided insight into the neural 
mechanisms underlying therapeutic change, they have not provided neural predictors of 
treatment outcomes for individual patients. The dorsolateral PFC might be a particularly 
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promising region, since increased activity in this area in response to a working memory task 
predicted good outcomes following CBTp12. Additionally, activation in networks including 
the amygdala and parietal lobule, which have been implicated in the neural mechanism of 
CBTp, have been found to predict individual response to CBT for social anxiety disorder16. 
However, no study to date has examined whether pre-therapy neural responses to facial affect 
can be used to make individual predictions about CBTp outcomes.  
 
The present study used the dataset of a case-controlled study that previously found that CBTp 
led to significant changes in the functional neurobiology of social threat processing, 
compared to treatment-as-usual48. Here, we employ multivariate pattern analysis to identify 
predictors of response to CBTp from pre-therapy functional MRI. We employed a two-step 
methodology. The first step involved identification of potentially predictive regions and the 
second step involved formation of a predictive model that utilised region-specific activation 
patterns to make a function that can make predictions at the individual patient level. We 
examined all available forms of facial affect processing, allowing the machine learning model 
to identify the specificity of the activation patterns for each facial condition for predicting 
treatment response in different symptom domains. We hypothesised that improvement in 
positive psychotic symptoms and depressive symptoms would be uniquely predicted by 
neural responses to threat-related (including ambiguous ‘neutral’ faces in addition to angry 
and fearful faces) and prosocial affect (happy faces), respectively. Caveated by the data-
driven approach and the absence of studies investigating predictors of CBTp outcomes from 
social affective neural processing, we hypothesised that the dorsolateral PFC and the 
amygdala, suggested to be implicated in the neurobiological mechanism underlying CBTp47, 
would predict post-CBTp improvement in both positive psychotic and affective symptoms.  
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Materials & methods 
Participants & design 
Participants were 38 patients who received either treatment-as-usual (TAU group) or CBTp 
on top of their regular care (+CBTp group), in a case-control cohort study described in detail 
elsewhere (see48). This previous study identified changes both in symptoms and in 
neurobiology in the +CBTp group (n=22) that were not found in the TAU group (n=16). The 
present study focused on the +CBTp group and the TAU group was used for validation of the 
predictive model in an independent sample. Diagnosis was established at baseline using the 
Structured Clinical Interview for DSM-IV (SCID)50. Symptoms were assessed using the 
Positive and Negative Syndrome Scale (PANSS)51 for psychotic symptoms and the Beck 
Depression Inventory (BDI)52 for depressive symptoms. All participants were scanned at the 
start of the study. Symptoms were reassessed after approximately six to eight months of TAU 
or TAU +CBTp. All participants were taking a stable dose of antipsychotic medication for a 
minimum of three months before the start of the study, which remained unchanged during the 
study. The study was approved by the joint research ethics committee of South London and 
Maudsley NHS trust and the Institute of Psychiatry in London (ref: 209/02). All participants 
provided written informed consent after explanation of the study procedures. Study 
procedures are reported in full elsewhere48.  
 
Functional MRI task 
A detailed description of the task and functional MRI acquisition can be found in the original 
study48. Participants performed an implicit facial affect task during the scanning session, in 
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which they were presented with monochrome faces portraying fear (signalling sources of 
threat in the environment, i.e. indirect threat), anger (direct threat), happiness (prosocial 
affect), or neutral (ambiguous threat) expressions48. Participants had to press a button to 
indicate the gender of the face upon each facial presentation. The task was set up as a block 
design. Each block consisted of 8 trials in which the same facial expression was presented 
(3.75 s per face, 30 seconds in total). Participants were presented with four blocks of each 
condition (i.e. fearful, angry, happy, and neutral faces), fully counterbalanced.  Between these 
blocks there were 4 baseline trials in which empty oval frames matched for luminance but 
without the face inside were shown (3.75 s per oval frame), and a left/right button press was 
required on each trial.  
 
Functional MRI data acquisition and analysis 
Data were collected on a widely available 1.5 Tesla General Electric Signa clinical system 
(echo time 40 ms, repetition time 3 s, flip angle 90º, field of view 240 mm, slice thickness 7.0 
mm, interslice gap 0.7 mm). Two hundred and forty T2*-weighted images were acquired. 
Image pre-processing and data analyses were conducted using Statistical Parametric Mapping 
(SPM) version 12 (Wellcome Department of Imaging Neuroscience, 
www.fil.ion.ucl.ac.uk/spm). The multivariate pattern analysis was implemented in the Pattern 
Recognition for Neuroimaging Toolbox (PRoNTo) (www.mlnl.cs.ucl.ac.uk/pronto/)53, a 
machine learning toolbox that permits multivariate regression and classification analyses on 
neuroimaging data. Images were smoothed, normalized, slice time corrected and realigned. 
See the Supplementary Materials for further details on image pre-processing.   
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Activation associated with baseline symptoms 
To optimize accuracy and generalisability of model predictions, feature reduction techniques 
were employed before training of the machine learning model54. Feature selection involves 
selecting voxels that are considered informative and excluding those considered less or non-
informative about predictions, resulting in less noise and increased predictive power. We 
constrained our analyses16,55 to symptom-locked activation, given our focus on predicting 
symptom improvement. We also report an unconstrained (whole-brain) analysis in the 
Supplementary Materials. In a first step, univariate regression analysis was used to identify 
clusters associated with baseline positive psychotic and depressive symptoms, with baseline 
symptom scores being regressed separately onto activation for each facial condition. The 
regions included in the functionally defined masks are presented in the Supplementary Tables 
1 and 2. Functional masks were identified in the +CBTp group, which were then also 
independently evaluated in the separate TAU group, using a voxel-wise threshold of p < 
0.001 with a cluster size of at least 10 active voxels56. The resulting masks were used to 
constrain the multivariate pattern analysis that involved building of a predictive model at the 
group level to make predictions about symptom change (from pre- to post-intervention) at the 
individual patient level. 
 
Predicting symptom improvement following CBTp 
Multivariate regression models for neuroimaging data decode patterns of voxel values from 
the input images that continuously predict variability in the predicted variable53. Here, the 
inputs were contrast images for neutral, angry, fearful and happy faces to predict 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
improvement in positive psychotic symptoms (PANSS-P) and depressive symptoms (BDI) 
for each patient. To assess the contribution of each condition to the prediction of 
improvement in positive psychotic and depressive symptoms, brain responses to the facial 
conditions were simultaneously assessed in a multiple kernel learning model57. We also 
report follow-up analyses of models including only one facial condition in the Supplementary 
Materials. In the current study, the input voxels (features) were mean centred and normalized 
using the training data, and an indication of the model’s generalizability was obtained using 
cross-validation and permutation testing. Cross-validation allows for assessment of the 
generalizability of the model using the available data by partitioning the data into training 
and testing sets58. We report the Pearson’s correlation coefficient (r), the Mean Squared Error 
(MSE), and the √MSE to assess the agreement between the predicted and actual symptom 
scores. The MSE reflects the sum of squared differences between the actual and predicted 
change in symptoms for each patient divided by the total number of patients53 and the √MSE 
can be interpreted as the standard deviation of the variance in symptom scores that is 
unexplained by the model59. A nested-k-fold scheme was used. Permutation testing over 1000 
iterations was used to derive a p-value for the accuracy of the decision function58. Further 
details on model optimization, the cross-validation scheme, and permutation testing are 
reported in the Supplementary Materials. To visualise the decision function, voxel-wise 
weights were computed for all significant models. Additionally, a list of regions ranked 
according to their contribution to the decision function was provided using the atlas60 as 
implemented within PRoNTo.  
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Results 
Socio-demographic and clinical characteristics of the patient group 
Demographic, clinical and task performance characteristics have been reported in full 
elsewhere48. In the +CBTp group, participants were on average 35.7 (SD=7.8) years old and 
had completed an average of 13.9 (SD=3.3) years of education. Twenty participants were on 
atypical and 2 were on both atypical and typical antipsychotics. In the TAU group, 
participants were on average 39.2 (SD=9.37) years old and had completed an average of 13.6 
(SD=1.7) years of education. Fourteen participants were on atypical and 2 were on both 
atypical and typical antipsychotics. Both patient groups showed high gender discrimination 
accuracy (84.7%) across all conditions (i.e. fearful, angry, happy, and neutral faces)48. 
Performance was comparable to healthy controls, reported separately47. Depressive 
symptoms were frequently experienced in addition to positive psychotic symptoms, with over 
65% of participants experiencing symptoms in the mild to severe range. From pre-therapy to 
post-therapy time points, both groups showed variation in positive psychotic (+CBTp M=3.2, 
SD=3.9; TAU M=0.5, SD=4.0) and in depressive symptom scores (+CBTp M=5.3, SD=10.9, 
TAU M=0.1, SD=6.9). However, symptoms improved significantly in the +CBTp group only 
(Table 1). 
 
 
Predicting symptom improvement following CBTp 
Improvement in positive psychotic symptoms was uniquely predicted by activation elicited 
by all types of threat-related affect (i.e. ambiguous ‘neutral’ faces that are often perceived as 
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threatening in psychosis, in addition to angry, and fearful faces) (r=0.63, p=0.003) (Table 2). 
Activation in frontal, sensorimotor, and hippocampal regions contributed most strongly to the 
predictive model (Table 3). However, the profile of activation was confined to fewer regions 
for angry and fearful faces compared to the more widespread profile of activation for neutral 
faces (Supplementary Table 3). Activation elicited by neutral faces contributed most strongly 
to the model followed by equivalent contributions from activation for angry and fearful faces 
(Figure 1). Follow-up analyses of models including only one facial condition revealed that 
activation elicited by angry, fearful, and neutral faces was predictive of improvement in 
positive psychotic symptoms, but activation elicited by happy faces was not (Supplementary 
Table 4).  
 
 
Improvement in depressive symptoms was uniquely predicted by activation elicited by fearful 
and happy faces (r=0.31, p=0.05) (Table 2). Activation in frontal and motor regions 
contributed most strongly to the predictive model (Table 3). Activation in the superior frontal 
gyrus solely contributed to the predictive model for fearful faces whereas a widespread 
pattern of activation across frontal, sensorimotor, limbic, and occipital regions contributed to 
the predictive model for happy faces (Supplementary Table 5). Activation elicited by fearful 
faces contributed most strongly to the model followed by activation for happy faces (Figure 
2). Follow-up analyses of models including only one facial condition revealed that activation 
elicited by fearful and happy faces was predictive but activation elicited by neutral faces was 
not (Supplementary Table 4). Activation elicited by angry faces could not be assessed since 
no activation was associated with symptoms at baseline.  
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Assessment of predictive models in independent treatment-as-usual group 
The assessment of the predictive models in the TAU group revealed that changes in both 
positive psychotic (r=-0.39, p=0.46) and depressive symptoms (r=-0.05, p=0.31) following 
TAU could not be predicted using the multiple kernel learning model (Table 4). Whilst the 
pattern was similar in terms of which facial conditions predicted changes in positive 
psychotic and depressive symptoms, with activation for neutral and fearful faces being the 
strongest predictor for changes in positive psychotic and depressive symptoms, respectively, 
the overall model did not reach significance (Supplementary Figure 1, 2).  
 
 
Discussion 
This proof-of-concept study set out to establish novel predictors from neural processing of 
social affective information by applying multivariate pattern analysis to pre-treatment 
functional MRI data. This research strategy bridges the gap between studies revealing 
associations between brain changes and CBTp outcomes61 and potentially clinically useful 
biomarkers that can inform understanding of treatment mechanisms and provide a step 
towards predictions of outcome and treatment planning for individual patients. The findings 
showed, to our knowledge for the first time, that machine learning methods can be used to 
build a model that can predict response to CBTp for each patient from pre-therapy neural 
responses to social affective information. In line with our hypotheses, we found a double 
dissociation between the valence of social affective information and the type of symptoms 
predicted. Whereas the brain activation pattern in response to angry (direct threat) and neutral 
(ambiguous threat) faces uniquely predicted improvement in positive psychotic symptoms, 
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the brain activation pattern in response to happy faces (prosocial affect) uniquely predicted 
improvement in depressive symptoms. In contrast, neural responses to fearful faces (indirect 
threat) predicted improvement in both positive psychotic and depressive symptoms.  
 
These findings also highlight the potential for this approach to inform clinical decision-
making. Caveated by a need for more research with larger samples, it may be possible to use 
limited predicted symptom improvement for a given patient to better tailor their treatment 
plan. One possibility is that CBTp may be augmented with other interventions19. 
Alternatively, it may be possible to use baseline neurobiological responses to social affect to 
plan and tailor the focus of therapy, such as spending more time engaging the client or a 
specific focus on modifying bias towards threatening social information. Considering the 
protracted duration of psychological therapy in which clinical signs of improvement may not 
be apparent for many weeks from the start of therapy, a robust biomarker may also act as an 
incentive to motivate the patient and increase compliance in addition to increasing the 
response rate in a stratified population. The clinical promise of this approach is underlined by 
the finding that clinically relevant stimuli can be used as assays for making specific 
predictions about different symptom domains and is supported by the growing interest in 
machine learning to optimise treatment outcomes16,62,63.  
 
It is interesting that processing of ambiguous ‘neutral’ faces was a stronger predictor of 
treatment response for positive psychotic symptoms than more directly threatening angry 
faces. One possible explanation for this finding is that processing of ambiguous stimuli 
particularly involves activation related to appraisals that are re-framed as part of CBTp. 
Namely, ambiguous stimuli have sensory characteristics that are less defined, thereby 
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allowing appraisals to have a stronger influence on their perception and interpretation. 
Evidence suggests that patients with psychosis appraise even mildly anomalous experiences 
as more threatening compared to healthy individuals, remitted patients, and individuals with 
similar psychotic experiences but without a need for care64–66. Therefore, processing of 
ambiguous stimuli might most strongly reflect threatening appraisals. Neural evidence for an 
over- or misattribution of threat involves elevated activation to neutral or ambiguous 
stimuli24,25,67, which has been attributed to aberrant salience perception68. This suggests that 
neutral or ambiguous stimuli may convey subtle information to which patients with psychosis 
are particularly sensitive, resulting in brain responses to ambiguous facial expressions not 
only reliably differentiating patients from healthy controls24 but also those who will respond 
well from those who will respond poorly. Processing of ambiguous stimuli might therefore 
most strongly reflect threatening appraisals. Since recent studies have shown that appraisals 
of symptoms mediate changes in outcome69 the finding that threat-related activation, in 
particular, activation in response to ambiguous ‘neutral faces’, predicted improvement in 
positive psychotic symptoms suggests that CBTp most likely improves psychotic symptoms 
in those endorsing more threatening appraisals of neutral or ambiguous stimuli25. However, 
this claim is at present speculative and requires more sophisticated measures to be 
substantiated.  
 
Brain activation in response to prosocial affect (happy faces) was unique in predicting 
improvement in depressive symptoms and not positive psychotic symptoms. However, brain 
activation in response to fearful faces emerged as an additional, and stronger, predictor of 
improvement in depressive symptoms than brain activation in response to happy faces. 
Enhanced brain responses to fearful faces were found to be associated with baseline 
depressive symptoms in this clinical group9 and reduced following CBTp in previous 
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analyses48. Additionally, the finding that processing of both happy and fearful faces could 
predict improvement in depressive symptoms is in line with neuroimaging studies revealing 
both hypo-responses to positive and hyper-responses to negative facial expressions in 
depression36. These findings suggest that CBTp most likely improves depressive symptoms 
in those with mood-congruent processing biases that are reduced by exploring the impact of 
thoughts and behaviours on depressive symptoms.  
 
Supporting our predictions, activity in the dorsolateral prefrontal cortex was important for 
predicting improvement in both positive psychotic and depressive symptoms. However, 
contrary to our hypothesis, the hippocampus emerged as a stronger predictor of improvement 
in positive psychotic symptoms than the amygdala. The dorsolateral prefrontal cortex and 
hippocampus are part of the dorsal system, which is involved in the regulation of emotions27. 
The predictive power of activation in the dorsal system supports the idea that CBTp may 
improve positive psychotic symptoms by facilitating patients’ ability to re-appraise their 
threatening experiences27. Interestingly, a number of sensorimotor regions, including the 
supplementary motor area, as well as visual regions, including the occipital and fusiform 
gyrus, also emerged as important predictors of improvement in both positive psychotic and 
depressive symptoms. Sensorimotor regions are, together with frontal regions, important for 
generating situation-specific behavioural responses33. The contribution of sensorimotor 
regions to predictions suggests an important role for behavioural techniques in improving 
both positive psychotic and depressive symptoms, by promoting change in unhelpful 
behaviours that contribute to the maintenance of delusional beliefs and mood worsening. 
Together, these findings suggest that a combination of threat-regulation and action 
preparation, as well as higher-order cognitive processes are key to predicting improvement in 
positive psychotic and depressive symptoms.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
Whilst the dorsolateral PFC was an important predictor of symptom improvement, it was not 
a stronger predictor than a large number of regions across sensorimotor and midbrain regions. 
One possibility is that the present task did not actively recruit higher-order cognitive 
processes such as reappraisal because participants were not explicitly prompted to process the 
affective component of the stimuli. Additionally, these findings need to be caveated by the 
focus on symptom-locked activation, which omitted other areas from the analysis. A 
Supplementary whole-brain analysis addressed this issue, and although the pattern was 
similar in terms of which facial conditions predicted changes in symptoms, the overall model 
did not reach significance (Supplementary Table 6, 7). Despite these constraints, the finding 
that activation in the dorsal system, including the dorsolateral PFC and hippocampus, was 
important for predicting improvement in positive psychotic symptoms, supports the idea that 
CBTp facilitates reappraisal through resources in higher-order brain regions that regulate 
those involved in threat and salience detection47.  
 
Although the present study successfully predicted symptom improvement, future studies 
including additional measurements would provide more encompassing predictions of 
treatment effects. The PANSS as an instrument has been criticised for only providing a 
measure of the presence and severity of psychotic symptoms, rather than the considerable 
variation in impact and quality of these experiences across individuals41. This is in line with 
previous work, which has shown that CBTp-led changes in brain responses to indirect threat 
were uncorrelated with the PANSS48. Future studies should explore measures that consider 
symptom dimensions such as power beliefs and distress to provide further insight into the 
predictors of treatment outcomes. Additionally, there is promise in exploring whether threat 
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processing as a predictor is a state or trait marker. State and trait features are likely to 
influence the development and maintenance of threatening appraisals along different 
pathways, including attentional, attributional, and reasoning biases as well as safety 
behaviours27. Elucidating these features might help guide effective treatment strategies at the 
individual patient level.  
 
Whilst the model identified predicted response to CBTp, it did not predict response in the 
independent TAU group. Caveated by the limited change in symptoms in the TAU group, 
these results may speak to the specificity of the findings in predicting response to CBTp 
rather than symptom changes per se. Future research with two active treatment groups can 
provide further insight into the specific predictors of response to CBTp. Additionally, the 
specificity of the facial conditions for predicting improvement in different symptom domains 
is further underlined by the similar contribution of the facial conditions to predictions in the 
+CBTp and independent TAU group (Supplementary Figure 1, 2).  
 
Although the sample size of the present study is comparable to other machine learning 
studies in psychiatry16,55,70, future studies with larger samples are warranted. The patient 
group reported here is likely to be representative of routine clinical practice, having been 
recruited from a clinic as part of routine care. However, further research with larger and 
independent samples of patients receiving CBTp should be undertaken to further establish the 
utility of machine learning approaches to predicting treatment response.  Additionally, the 
use of higher resolution functional MRI to investigate subcortical predictors should be further 
explored as well as the inclusion of behavioural and clinical measures into predictive models 
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considering that the most optimal predictions likely require different sources of 
information71. 
 
In summary, the present study supports the utility of machine learning methods to predict 
how people will respond when offered CBTp. The clinical utility of this approach is further 
underscored by the finding that neural responses to threat-related affect (i.e. ambiguous 
‘neutral’ faces that are typically perceived as threatening in psychosis, in addition to angry 
and fearful faces) specifically predicted improvement in positive psychotic symptoms, 
whereas neural responses to fearful and happy faces predicted improvement in depressive 
symptoms. These findings suggest that CBTp most likely improves psychotic and affective 
symptoms in those endorsing more threatening appraisals and mood-congruent processing 
biases, respectively, which are explored and reframed as part of the therapy. Caveated by 
further research in larger and independent samples of patients receiving CBTp, baseline 
activation patterns in response to social affective information may assist in individual therapy 
formulations by informing the focus of the therapy on threat or mood-congruent processing 
biases that are addressed through different techniques including the generation of alternative 
explanations for psychotic experiences and the exploration of mood on thinking styles. 
Machine learning methods may therefore become a valuable tool for mapping the neural 
correlates of these biases to make predictions about treatment outcomes for each patient. This 
promising approach may be further refined, for example by including additional predictors, 
such as structural and connectivity measures. It is our hope that these methods may ultimately 
go beyond treatment selection and be used to tailor and refine the psychological intervention 
offered to individual patients.  
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Table 1. Means and standard deviations for positive psychotic and depressive symptoms pre- 
and post-therapy. 
   
 Depressive symptomsa Positive psychotic symptomsb 
   
 Mean (SD) Mean (SD) 
CBTp   
Pre-therapy 16.2 (8.3) 18.1 (4.8) 
Follow-up 11.5* (9.9) 14.9* (4.1) 
   
TAU   
Pre-therapy 15.9 (10.4) 18.6 (3.2) 
Follow-up 15.8 (12.1) 18.1 (3.3) 
   
aDepressive symptoms were assessed using the Beck Depression Inventory52 
bPositive psychotic symptoms were assessed using the positive psychotic symptom rating on 
the Positive and Negative Syndrome Scale51 
*Significant symptom reduction (p < 0.05) at follow up relative to baseline 
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Table 2. Predictive accuracy of multivariate models for response to cognitive behavioral 
therapy for psychosis.  
     r  P(r)    MSE  P(MSE) √MSE 
         
Positive psychotic 
symptomsa 
0.63  0.003*  8.65  0.003* 2.94 
Neutral faces (57.6%)         
Angry faces (22.2%)         
Fearful faces (20.2%)         
Happy faces (0%)         
         
Depressive symptomsb 0.31  0.05*  103.73  0.04* 10.18 
Fearful faces (73.1%)         
Happy faces (25.7%)                
Neutral faces (1.2 %)         
Angry facestc                                    
         
Neutral faces (ambiguous threat). Angry faces (direct threat). Fearful faces (indirect threat). 
Happy faces (prosocial affect). Abbreviations: MSE, mean squared error. 
aPositive psychotic symptoms were assessed using the positive psychotic symptom rating on 
the Positive and Negative Syndrome Scale51 
bDepressive symptoms were assessed using the Beck Depression Inventory52 
cNot included in multivariate analysis because no symptom-locked activity at baseline 
*p  0.05  
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Table 3. Top 3 predictors for positive psychotic and depressive symptoms and their relative 
weights in predictive power (percentage of the total weights in the decision function); clusters 
< 10 active voxels excluded.  
       
Anatomical region MNI coordinates  Brodmann 
area 
weight 
(%) 
size 
(voxels) 
 x y z     
        
Positive psychotic symptoms        
‘Neutral’ faces (57.6%)        
R superior frontal gyrus 14   25 51          8    5.4 21 
R cerebellum  10   -76 -22     5.4 46 
L supplementary motor area -42   -12  16  6    4.4 26 
        
Fearful faces (22.2%)        
L precentral gyrus -26   32  26          4    9.9 81 
L superior frontal gyrus -32  -10 58          6    9.9 40 
R middle cingulum  10    22  36          8    7.8 16 
        
Angry faces (20.2%)        
R inferior occipital gyrus 42   -76  -12        19  44.6 39 
R hippocampus 28   -12  -20   38.5 23 
R inferior temporal gyrus 48   -64  -10        37  16.9 21 
        
Happy faces (0%)        
R inferior frontal gyrus 56    32   8        45          0 14 
          
Depressive symptomsa          
Fearful faces (73.1%)        
L superior frontal gyrus -10    28  52          8  74.0 20 
        
Happy faces (25.7%)        
L inferior frontal gyrus -52  24 28        44  12.7 84 
R precentral gyrus 42    0 52          6    9.8 21 
L fusiform gyrus -40   -38 -20        37    5.8 62 
        
‘Neutral’ faces (1.2%)        
R hippocampus 28   -22 -14        54  13.7 25 
L precentral gyrus -10   -34 -30          6    9.6 48 
R parahippocampal gyrus 28   -11 -27        36     7.1 16 
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Neutral faces (ambiguous threat). Angry faces (direct threat). Fearful faces (indirect threat). 
Happy faces (prosocial affect). aNo predictors for angry faces because no symptom-locked 
activity at baseline. 
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Table 4. Assessment of predictive models in independent treatment-as-usual group.  
     r  P(r)  MSE  P(MSE) √MSE 
         
Positive psychotic symptomsa    -0.39  0.46  21.21  0.67 4.60 
Neutral faces (62.9%)         
Fearful faces (33.8%)         
Happy faces (3.3%)         
Angry faces (0%)         
         
Depressive symptomsb    -0.05  0.31  52.24  0.67 7.23 
Fearful faces (61.1%)         
Happy faces (26.5%)         
Neutral faces (11.9 %)         
Angry facesc                 
         
Neutral faces (ambiguous threat). Angry faces (direct threat). Fearful faces (indirect threat). 
Happy faces (prosocial affect). Abbreviations: MSE, mean squared error. 
aPositive psychotic symptoms were assessed using the positive psychotic symptom rating on 
the Positive and Negative Syndrome Scale51 
bDepressive symptoms were assessed using the Beck Depression Inventory52 
cNot included in multivariate analysis because no symptom-locked activity at baseline 
*p  0.05  
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Figure 1. Baseline brain responses to threat-related affect (ambiguous ‘neutral’ faces that are 
typically perceived as threatening in psychosis, in addition to fearful and angry faces) predict 
improvement in positive psychotic symptoms following CBTp. The multiple kernel learning 
model is significant (r=0.63, p=0.003). The bar graph shows the relative contribution of each 
facial condition to the decision function. Top, from left to right: x=48, 26, y=-12. Bottom, 
from left to right: y=-18, 39, 56.  
 
Figure 2. Baseline brain responses to fearful faces (indirect threat) and happy faces (prosocial 
affect) predict improvement in depressive symptoms following CBTp. The multiple kernel 
learning model is significant (r=0.31, p=0.05). The bar graph shows the relative contribution 
of each condition to the decision function. Top, from left to right: x=14, 41, 53. Bottom, from 
left to right: y=4, 17, 29.  
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Highlights 
 Machine learning models using neuroimaging data can predict response to CBTp. 
 Neural responses to social threat predicted improvement in psychotic symptoms. 
 Activation related to different social stimuli predicted distinct symptom domains.  
 Predictors included activity in the hippocampus, frontal, and sensorimotor regions. 
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